Physician profile

John B Baccus

Pain Medicine (Anesthesiology) · Elkhart, IN

NPI 1508831157

$680.15

in general payments reported to CMS, 2019-2025

11 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$83.30

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbott Laboratories $387.07 2019-2023 Proclaim
Boston Scientific Corporation $66.26 2019-2020
Nevro Corp. $44.17 2019-2020
Medtronic, INC. $37.66 2022
Pacira Therapeutics, INC. $32.72 2019
Abbvie INC. $24.84 2022
Mayne Pharma Commercial LLC $24.11 2020
Painteq LLC $18.72 2023 Painteq
Bioventus LLC $18.38 2020
Biodelivery Sciences International, INC. $14.48 2020
Pfizer INC. $11.74 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John B Baccus

$680.15

in general payments reported 2019-2025

Years
2019-2023
Top company
Abbott Laboratories

https://glasscript.com/doctor/204499/john-b-baccus

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.